<p>Checkpoint Therapeutics（纳斯达克：CKPT - 获取免费报告）于周五公布了季度财报。该公司报告每股收益为（$0.69），低于分析师一致预期的（$0.22），差距为（$0.47），据 Zacks 报道。</p>
<h2>Checkpoint Therapeutics 股票上涨 0.2%</h2>
<p>CKPT 在周五的交易时段上涨了$0.01，达到$4.04。该公司股票交易量为 522,554 股，而其平均交易量为 1,124,079 股。该股票的市值为 1.9729 亿美元，市盈率为-2.20，贝塔值为 1.41。Checkpoint Therapeutics 的 1 年最低价为$1.38，1 年最高价为$4.50。该股票的 50 日移动平均价为$3.32，200 日移动平均价为$3.25。</p>
<h2>分析师评级变动</h2>
<p>CKPT 成为多份研究分析师报告的主题。HC Wainwright 在 3 月 11 日的报告中重申了 “中性” 评级，并将 Checkpoint Therapeutics 的目标价设定为$4.10。Lake Street Capital 在 3 月 10 日的研究报告中重新发布了 “持有” 评级，并将目标价下调至$4.10（之前为$7.00）。最后，D. Boral Capital 在 3 月 10 日的报告中重申了 “买入” 评级，并将目标价下调至$4.80（之前为$9.00）。</p>
<p><strong>阅读我们关于 CKPT 的最新股票报告</strong></p>
<h2>Checkpoint Therapeutics 的内部买卖</h2>
<p>在其他 Checkpoint Therapeutics 的新闻中，首席财务官 William Garrett Gray 在 2 月 6 日的交易中出售了 74,110 股公司的股票。该股票以平均价格$3.67 出售，总交易额为$271,983.70。交易后，首席财务官现在持有 1,458,644 股公司的股票，价值$5,353,223.48。此次交易使其持股减少了 4.84%。该出售在向证券交易委员会的备案中披露，相关信息可通过此链接获取。此外，首席执行官 James F. Oliviero III 在 2 月 7 日的交易中出售了 9,233 股公司的股票。该股票以平均价格$3.41 出售，总价值为$31,484.53。出售完成后，首席执行官现在直接持有 3,785,350 股公司的股票，价值约为$12,908,043.50。此次交易使其持股减少了 0.24%。该出售的披露信息可在此找到。在过去三个月中，内部人士已出售 93,674 股公司股票，价值$336,011。内部人士持有公司股票的比例为 2.10%。</p>
<h2>关于 Checkpoint Therapeutics</h2>
<p>（获取免费报告）</p>
<p>Checkpoint Therapeutics, Inc.是一家临床阶段的免疫疗法和靶向肿瘤学公司，专注于在美国和国际上获取、开发和商业化新型治疗方案，以治疗实体肿瘤癌症患者。该公司的主要抗体产品候选药物是 Cosibelimab，目前正在进行针对选定复发或转移性癌症患者的 1 期临床试验；CK-302 是一个针对血液恶性肿瘤和实体肿瘤的预临床试验产品候选药物。</p>
<h2>阅读更多</h2>
<ul>
<li>我们更看好的五只股票，而不是 Checkpoint Therapeutics</li>
<li>投资商品：它们是什么？如何投资？</li>
<li>MarketBeat 周度回顾 – 03/24 - 03/28</li>
<li>深入了解买卖差价</li>
<li>现在应该购买 UPS 股票吗？深入分析其 5 年低点</li>
<li>ETF 会支付股息吗？你需要知道的</li>
<li>4 只医疗保健股票大幅上涨——还有更多收益在后</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0tQVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0tQVA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 Checkpoint Therapeutics 吗？</h2>
<p>在你考虑 Checkpoint Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Checkpoint Therapeutics 并不在名单上。</p>
<p>虽然 Checkpoint Therapeutics 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

Checkpoint医疗

<p>Checkpoint Therapeutics（纳斯达克代码：CKPT）报告季度每股收益为（$0.69），低于分析师预期的（$0.22），差距为（$0.47）。股价上涨 0.2%，至$4.04，市值为 1.9729 亿美元。分析师的评级意见不一，HC Wainwright 和 Lake Street Capital 分别维持 “中性” 和 “持有” 评级，而 D. Boral Capital 则给予 “买入” 评级。内部交易方面，首席财务官 William Garrett Gray 出售了 74,110 股，首席执行官 James F. Oliviero III 出售了 9,233 股。该公司专注于免疫疗法和肿瘤治疗</p>

<p>Checkpoint Therapeutics (NASDAQ:CKPT - Get Free Report) announced its quarterly earnings results on Friday. The company reported ($0.69) earnings per share for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.47), Zacks reports.</p>
<div class="lb-trans"><p>Checkpoint Therapeutics（纳斯达克：CKPT - 获取免费报告）于周五公布了季度财报。该公司报告每股收益为（$0.69），低于分析师一致预期的（$0.22），差距为（$0.47），据 Zacks 报道。</p>
</div><h2>Checkpoint Therapeutics Stock Up 0.2 %</h2>
<div class="lb-trans"><h2>Checkpoint Therapeutics 股票上涨 0.2%</h2>
</div><p>CKPT traded up $0.01 during trading hours on Friday, hitting $4.04. 522,554 shares of the company's stock were exchanged, compared to its average volume of 1,124,079. The stock has a market cap of $197.29 million, a price-to-earnings ratio of -2.20 and a beta of 1.41. Checkpoint Therapeutics has a 1-year low of $1.38 and a 1-year high of $4.50. The stock's 50-day moving average is $3.32 and its two-hundred day moving average is $3.25.</p>
<div class="lb-trans"><p>CKPT 在周五的交易时段上涨了$0.01，达到$4.04。该公司股票交易量为 522,554 股，而其平均交易量为 1,124,079 股。该股票的市值为 1.9729 亿美元，市盈率为-2.20，贝塔值为 1.41。Checkpoint Therapeutics 的 1 年最低价为$1.38，1 年最高价为$4.50。该股票的 50 日移动平均价为$3.32，200 日移动平均价为$3.25。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>CKPT has been the topic of a number of research analyst reports. HC Wainwright restated a &#34;neutral&#34; rating and set a $4.10 price objective on shares of Checkpoint Therapeutics in a report on Tuesday, March 11th. Lake Street Capital reissued a &#34;hold&#34; rating and issued a $4.10 price target (down previously from $7.00) on shares of Checkpoint Therapeutics in a research note on Monday, March 10th. Finally, D. Boral Capital restated a &#34;buy&#34; rating and issued a $4.80 price target (down from $9.00) on shares of Checkpoint Therapeutics in a report on Monday, March 10th.</p>
<div class="lb-trans"><p>CKPT 成为多份研究分析师报告的主题。HC Wainwright 在 3 月 11 日的报告中重申了 “中性” 评级，并将 Checkpoint Therapeutics 的目标价设定为$4.10。Lake Street Capital 在 3 月 10 日的研究报告中重新发布了 “持有” 评级，并将目标价下调至$4.10（之前为$7.00）。最后，D. Boral Capital 在 3 月 10 日的报告中重申了 “买入” 评级，并将目标价下调至$4.80（之前为$9.00）。</p>
</div><p><strong>Read Our Latest Stock Report on CKPT</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 CKPT 的最新股票报告</strong></p>
</div><h2>Insider Buying and Selling at Checkpoint Therapeutics</h2>
<div class="lb-trans"><h2>Checkpoint Therapeutics 的内部买卖</h2>
</div><p>In other Checkpoint Therapeutics news, CFO William Garrett Gray sold 74,110 shares of the business's stock in a transaction that occurred on Thursday, February 6th. The stock was sold at an average price of $3.67, for a total transaction of $271,983.70. Following the transaction, the chief financial officer now owns 1,458,644 shares of the company's stock, valued at $5,353,223.48. The trade was a 4.84 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which is available through this hyperlink. Also, CEO James F. Oliviero III sold 9,233 shares of the firm's stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $3.41, for a total value of $31,484.53. Following the completion of the sale, the chief executive officer now directly owns 3,785,350 shares of the company's stock, valued at approximately $12,908,043.50. The trade was a 0.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 93,674 shares of company stock worth $336,011. Insiders own 2.10% of the company's stock.</p>
<div class="lb-trans"><p>在其他 Checkpoint Therapeutics 的新闻中，首席财务官 William Garrett Gray 在 2 月 6 日的交易中出售了 74,110 股公司的股票。该股票以平均价格$3.67 出售，总交易额为$271,983.70。交易后，首席财务官现在持有 1,458,644 股公司的股票，价值$5,353,223.48。此次交易使其持股减少了 4.84%。该出售在向证券交易委员会的备案中披露，相关信息可通过此链接获取。此外，首席执行官 James F. Oliviero III 在 2 月 7 日的交易中出售了 9,233 股公司的股票。该股票以平均价格$3.41 出售，总价值为$31,484.53。出售完成后，首席执行官现在直接持有 3,785,350 股公司的股票，价值约为$12,908,043.50。此次交易使其持股减少了 0.24%。该出售的披露信息可在此找到。在过去三个月中，内部人士已出售 93,674 股公司股票，价值$336,011。内部人士持有公司股票的比例为 2.10%。</p>
</div><h2>About Checkpoint Therapeutics</h2>
<div class="lb-trans"><h2>关于 Checkpoint Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.</p>
<div class="lb-trans"><p>Checkpoint Therapeutics, Inc.是一家临床阶段的免疫疗法和靶向肿瘤学公司，专注于在美国和国际上获取、开发和商业化新型治疗方案，以治疗实体肿瘤癌症患者。该公司的主要抗体产品候选药物是 Cosibelimab，目前正在进行针对选定复发或转移性癌症患者的 1 期临床试验；CK-302 是一个针对血液恶性肿瘤和实体肿瘤的预临床试验产品候选药物。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>阅读更多</h2>
</div><ul>
<li>Five stocks we like better than Checkpoint Therapeutics</li>
<li>Investing in Commodities: What Are They? How to Invest in Them</li>
<li>MarketBeat Week in Review – 03/24 - 03/28</li>
<li>A Deeper Look at Bid-Ask Spreads</li>
<li>Should You Buy UPS Stock Now? Deep Dive Into Its 5-Year Low</li>
<li>Do ETFs Pay Dividends? What You Need to Know</li>
<li>4 Healthcare Stocks With Massive Gains—and More to Come</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Checkpoint Therapeutics</li>
<li>投资商品：它们是什么？如何投资？</li>
<li>MarketBeat 周度回顾 – 03/24 - 03/28</li>
<li>深入了解买卖差价</li>
<li>现在应该购买 UPS 股票吗？深入分析其 5 年低点</li>
<li>ETF 会支付股息吗？你需要知道的</li>
<li>4 只医疗保健股票大幅上涨——还有更多收益在后</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0tQVA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=CKPT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Checkpoint Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 Checkpoint Therapeutics 吗？</h2>
</div><p>Before you consider Checkpoint Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Checkpoint Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Checkpoint Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Checkpoint Therapeutics 并不在名单上。</p>
</div><p>While Checkpoint Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Checkpoint Therapeutics 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Checkpoint Therapeutics（纳斯达克股票代码：CKPT）公布季度财报结果